Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Blueprint Medicines Corp (BPMC)

Blueprint Medicines Corp (BPMC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,977,706
  • Shares Outstanding, K 55,731
  • Annual Sales, $ 66,510 K
  • Annual Income, $ -347,690 K
  • 60-Month Beta 0.95
  • Price/Sales 88.25
  • Price/Cash Flow N/A
  • Price/Book 4.45
Trade BPMC with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -1.59
  • Number of Estimates 9
  • High Estimate -0.85
  • Low Estimate -2.07
  • Prior Year -1.35
  • Growth Rate Est. (year over year) -17.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
93.13 +15.17%
on 11/02/20
108.50 -1.15%
on 10/29/20
+2.17 (+2.06%)
since 10/27/20
3-Month
66.20 +62.02%
on 09/11/20
108.50 -1.15%
on 10/29/20
+33.35 (+45.12%)
since 08/27/20
52-Week
43.29 +147.77%
on 03/16/20
108.50 -1.15%
on 10/29/20
+30.13 (+39.06%)
since 11/27/19

Most Recent Stories

More News
SmarTrend Watching for Potential Pullback in Shares of Blueprint Medici After 1.39% Gain

Blueprint Medici (NASDAQ:BPMC) traded in a range yesterday that spanned from a low of $103.95 to a high of $105.86. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high...

BPMC : 107.26 (+1.84%)
Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FDA Approval of GAVRETO™ (pralsetinib)

, /PRNewswire-PRWeb/ -- Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health...

BPMC : 107.26 (+1.84%)
Blueprint Medicines To Present Broad Range of Data Reinforcing Commitment to Advance Patient Care in Systemic Mastocytosis at 62nd ASH Annual Meeting and Exposition

, /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced plans to report...

BPMC : 107.26 (+1.84%)
Blueprint Medici Shares Up 29.7% Since SmarTrend's Buy Recommendation (BPMC)

SmarTrend identified an Uptrend for Blueprint Medici (NASDAQ:BPMC) on September 17th, 2020 at $77.08. In approximately 2 months, Blueprint Medici has returned 29.70% as of today's recent price of $99.97....

BPMC : 107.26 (+1.84%)
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

, /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective...

BPMC : 107.26 (+1.84%)
Blueprint Medici Shares Up 26.5% Since SmarTrend's Buy Recommendation (BPMC)

SmarTrend identified an Uptrend for Blueprint Medici (NASDAQ:BPMC) on September 17th, 2020 at $77.08. In approximately 2 months, Blueprint Medici has returned 26.45% as of today's recent price of $97.47....

BPMC : 107.26 (+1.84%)
Blueprint Medicines (BPMC) Q3 Earnings Beat, Revenues Rise Y/Y

Blueprint Medicines' (BPMC) both bottom and the top line trump estimates in Q3. Ayvakit's sales rise sequentially.

RHHBY : 41.7300 (+1.04%)
HZNP : 70.55 (+2.39%)
BPMC : 107.26 (+1.84%)
FULC : 11.54 (+1.94%)
Blueprint Medicines (BPMC) Q3 Earnings and Revenues Surpass Estimates

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 71.96% and 31.67%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?...

BPMC : 107.26 (+1.84%)
Blueprint Medicines: 3Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Blueprint Medicines Corp. (BPMC) on Thursday reported third-quarter net income of $634 million, after reporting a loss in the same period a year earlier.

BPMC : 107.26 (+1.84%)
Blueprint Medicines Reports Third Quarter 2020 Financial Results

, /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported financial results...

BPMC : 107.26 (+1.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Blueprint Medicines Corp is an oncology company which is engaged in developing kinase inhibitors for genomically defined cancer subsets. Blueprint Medicines Corp is based in Cambridge, MA.

See More

Key Turning Points

2nd Resistance Point 109.77
1st Resistance Point 108.52
Last Price 107.26
1st Support Level 105.61
2nd Support Level 103.95

See More

52-Week High 108.50
Last Price 107.26
Fibonacci 61.8% 83.59
Fibonacci 50% 75.90
Fibonacci 38.2% 68.20
52-Week Low 43.29

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar